Skip to main content
. 2020 Dec 21;3(1):100049. doi: 10.1016/j.cytox.2020.100049

Table 3.

Abrogating inhibitory receptor signaling via CRISPR/Cas9-mediated genome editing to augment T cell effector function.

Target CAR In vitro
 In vivo
 Ref
IFN-γ TNF-α IL-2 CD107a GzmA GzmB GzmC GzmD Cytotoxicity Model IFN-γ IL-2 GzmB Tumor
PD-1 + + + + [57], [58], [59]
+ + Melanoma D [60]
CD19 + + Myeloid leukemia R [45]
CD133 = = = + Glioma D [63]
Glypican-3 + + + Hepatocellular carcinoma + + D [62]
Mesothelin + + + Breast cancer D [64]
CTLA-4 + + [66]
+ + Colorectal carcinoma D [65]
LAG-3 = = Raji Burkitt’s lymphoma R [67]

+, increased production; =, equal production; R, tumor regression; D, tumor outgrowth delayed. Blank indicates not reported.